抗哮喘生物制剂对共存慢性鼻窦炎的益处:真实世界研究
本研究基于Mayo Clinic 2016-2019年电子健康记录,纳入247例接受抗哮喘生物制剂且共存慢性鼻窦炎(CRS)的患者,采用配对分析比较治疗前后Lund-Mackay CT评分和SNOT-22评分。结果显示抗IL-5治疗与CT评分(整体CRS、CRSwNP亚组、CRSsNP亚组)及SNOT-22评分(整体CRS、CRSwNP亚组)显著改善相关;奥马珠单抗改善CT评分但未改善SNOT-22评分。
要点
- 抗IL-5生物制剂可改善整体CRS及CRSwNP患者的CT和SNOT-22评分。
- CRSsNP患者仅CT评分改善,SNOT-22未见显著改善。
- 奥马珠单抗改善CT评分但不改善SNOT-22评分。
核心结论
- 抗IL-5 agents与整体CRS组和CRSwNP亚组的CT及SNOT-22评分改善相关,CRSsNP患者仅CT评分改善。
- 奥马珠单抗改善CT评分但不改善SNOT-22评分。
- 启动生物制剂后22%的患者接受了ESS。
研究设计与样本
- 回顾性真实世界研究,基于Mayo Clinic 2016-2019年电子健康记录。
- 纳入247例接受抗哮喘生物制剂且共存CRS的患者,其中CRSwNP 181例(73.3%),CRSsNP 66例(26.7%)。
- 采用配对分析比较治疗前后Lund-Mackay CT评分和SNOT-22评分。
主要发现
- 抗IL-5干预与CT评分显著改善相关(整体CRS、CRSwNP亚组、CRSsNP亚组)。
- 抗IL-5干预与SNOT-22评分显著改善相关(整体CRS、CRSwNP亚组)。
- 奥马珠单抗组CT评分下降,但SNOT-22评分未下降。
- 206例(84.1%)接受了ESS,其中55例(22.3%)在生物制剂干预后手术(抗IL-5:16.5%;奥马珠单抗:27.8%)。
关键数值与推荐
- 生物制剂使用情况:奥马珠单抗51.0%,美泊利珠单抗46.6%,贝那利珠单抗10.5%,瑞利珠单抗1.6%,度普利尤单抗2.4%。
临床怎么用
- 抗IL-5生物制剂可用于改善共存CRS(尤其CRSwNP)的影像和症状评分。
- 奥马珠单抗治疗者需关注鼻部症状可能无明显改善。
- 启动生物制剂后仍有部分患者需行ESS,应个体化评估手术需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma and some chronic rhinosinusitis (CRS) subtypes are mediated by similar pathophysiologic mechanisms. The purpose of this study was to evaluate the effects of biologic therapy for asthma on co-existent CRS in the "real-world" setting. METHODS: A review of electronic health records (2016-2019) at Mayo Clinic was conducted to identify asthma patients treated with biologics who had co-existent CRS. Matched-pair analyses compared pretherapy and posttherapy Lund-Mackay computed tomography (CT) scores and 22-item Sino-Nasal Outcome Test (SNOT-22) scores. Performance of endoscopic sinus surgery (ESS) after initiating biologics was studied. RESULTS: We identified 247 patients who received anti-asthma biologic therapy and had co-existent CRS. Of these, 181 patients (73.3%) had CRS with nasal polyposis (CRSwNP) and 66 (26.7%) had CRS without nasal polyposis (CRSsNP). The biologics utilized were omalizumab (51.0%), mepolizumab (46.6%), benralizumab (10.5%), reslizumab (1.6%), and dupilumab (2.4%). Anti-interleukin-5 (anti-IL-5) intervention was associated with significant improvement in CT scores (CRS overall, CRSwNP subgroup, CRSsNP subgroup) and SNOT-22 scores (CRS overall, CRSwNP subgroup). Patients on omalizumab had a decrease in CT scores, but not SNOT-22 scores. ESS was performed in 206 patients (84.1%); 55 (22.3%) underwent surgery post-biologic intervention (anti-IL-5: 16.5%; omalizumab 27.8% of patients). CONCLUSION: Anti-IL-5 agents were associated with improved CT and SNOT-22 scores in the overall CRS group and in CRSwNP subgroup; CRSsNP patients showed improved CT scores only. Omalizumab improved CT but not SNOT-22 scores. ESS was performed in 22% of patients after initiating biologics. These real-world results may influence future trial designs and clinical applications of biologics for CRS. ©2021 ARSAAOA, LLC.
引用
- Bajpai S, Marino MJ, Rank MA, et al. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study. Int Forum Allergy Rhinol. 2021. PMID: 33527730. doi:10.1002/alr.22774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。